- GSK Pharma India’s third-quarter net income significantly surpassed expectations, reaching 2.3 billion rupees compared to 457.2 million rupees from the previous year.
- Analysts had estimated the net income to be 1.97 billion rupees.
- The company’s revenue increased by 18% year-over-year, totaling 9.49 billion rupees, which exceeded the forecast of 8.76 billion rupees.
- Total costs for the quarter were 6.76 billion rupees, marking a 12% increase from the previous year.
- GSK Pharma India reported other income at 350.7 million rupees, a 25% increase year-over-year.
- Investment analysts’ ratings for the company include 2 buys and 2 holds, with no sell recommendations.
A look at GlaxoSmithKline PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
GlaxoSmithKline PLC, a research-based pharmaceutical company, has received mixed Smart Scores indicating its long-term outlook. While the company scores well in Dividend and Growth, with scores of 4 and 3 respectively, its Value and Resilience scores are lower at 2. Momentum falls in the middle at 3. This suggests that GlaxoSmithKline offers a solid dividend and potential for growth, but may be less attractive in terms of value and resilience.
GlaxoSmithKline PLC operates in the pharmaceutical industry with a focus on vaccines, prescription drugs, over-the-counter medicines, and consumer health products. The company’s product portfolio spans various medical areas such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. Despite the mixed Smart Scores, GlaxoSmithKline’s diversified product offerings position it as a key player in the healthcare sector with opportunities for growth and income generation.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
